David Sarid
Overview
Explore the profile of David Sarid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giannatempo P, Machiels J, Sassa N, Arranz J, Fujii Y, Su W, et al.
Clin Genitourin Cancer
. 2025 Mar;
23(2):102273.
PMID: 40037029
Introduction: A post hoc analysis of efficacy and safety outcomes with pembrolizumab monotherapy was conducted in patients with advanced or metastatic urothelial carcinoma (UC) with pure transitional cell carcinoma (TCC)...
2.
Calvo E, Doger B, Carles J, Peer A, Sarid D, Eigl B, et al.
Oncologist
. 2025 Jan;
30(1).
PMID: 39832129
Background: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis, necessitating the investigation of novel treatments and targets. This study evaluated JNJ-70218902 (JNJ-902), a T-cell redirector targeting transmembrane protein with...
3.
Leong D, Fradet V, Niazi T, Selvanayagam J, Sabbagh R, Higano C, et al.
JACC CardioOncol
. 2024 Oct;
6(5):761-771.
PMID: 39479325
Background: There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to...
4.
Keizman D, Frenkel M, Peer A, Rosenbaum E, Sarid D, Leibovitch I, et al.
Nutrients
. 2023 Aug;
15(16).
PMID: 37630724
The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol-Modified...
5.
Rouvinov K, Levanon E, Peer A, Sarfaty M, Sarid D, Neiman V, et al.
Front Oncol
. 2023 Jun;
13:1151701.
PMID: 37293597
Background: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on...
6.
Kesler M, Cohen D, Levine C, Sarid D, Keizman D, Yossepowitch O, et al.
J Nucl Med
. 2023 Apr;
64(7):1030-1035.
PMID: 37116912
Although prostate-specific membrane antigen (PSMA) PET/CT has been shown valuable for staging biopsy-proven [B(+)] high-risk prostate cancer, elderly patients are occasionally referred for PSMA PET/CT without a preimaging confirming biopsy...
7.
Dekalo S, Kuten J, Campbell J, Mintz I, Bar-Yosef Y, Keizman D, et al.
Can Urol Assoc J
. 2022 Mar;
16(7):E381-E385.
PMID: 35230941
Introduction: Current guidelines do not support the use of pretreatment imaging in patients with favorable intermediate-risk prostate cancer. Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is more accurate...
8.
Keizman D, Frenkel M, Peer A, Kushnir I, Rosenbaum E, Sarid D, et al.
Nutrients
. 2021 Dec;
13(12).
PMID: 34959847
Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus pectin (PectaSol, P-MCP), a dietary polysaccharide, is an established antagonist of galectin-3, a...
9.
Kesler M, Kerzhner K, Druckmann I, Kuten J, Levine C, Sarid D, et al.
Eur J Nucl Med Mol Imaging
. 2021 Dec;
49(6):2077-2085.
PMID: 34957528
Purpose: The aim of the study was to elaborate the incidence and type of skeletal involvement in a large cohort of patients with newly diagnosed prostate cancer (PCa) referred for...
10.
Dekalo S, Kuten J, Mintz I, Fahoum I, Gitstein G, Keizman D, et al.
Prostate Cancer Prostatic Dis
. 2021 Apr;
24(3):910-916.
PMID: 33790418
Background: High-risk prostate cancer is associated with adverse pathology and unfavorable outcomes after radical prostatectomy. Ga-PSMA PET/CT is more accurate than conventional imaging for preoperative staging. We aimed to evaluate...